Syngene International Share Price Crashes 5% After Massive Q3 Net Profit Decline

Synopsis: Syngene International Limited reports 2.82% YoY revenue drop and a 88.56% YoY net profit decline in Q3 FY26 results.

This small-cap Pharma Stock, engaged in contract research, development, and manufacturing of pharmaceuticals, biologics, and chemicals for global biotech and pharma clients, crashed 5.28 percent after the company reported weak December quarterly results with an 88.56 percent YoY decrease in net profit.

With a market capitalization of Rs. 23,021.94 crores, the share of Syngene International Limited has reached an intraday low of Rs. 560.90 per equity share, down nearly 5.28 percent from its previous day’s close price of Rs. 592.15. Since then, the stock has retreated and is currently trading at Rs. 571.35 per equity share. 

Q3 FY26 Result Walkthrough:

Coming into the quarterly results of Syngene International Limited, the company’s consolidated revenue from operations decreased by 2.82 percent YOY, from Rs. 943.7 crore in Q3 FY25 to Rs. 917.1 crore in Q3 FY26, and grew slightly by 0.71 percent QoQ from Rs. 910.6 crore in Q2 FY26. Further, the company’s EBITDA has decreased by 25.50 percent, from Rs. 302 crore in Q3 FY25 to Rs. 225 crore in Q3 FY26. 

In Q3 FY26, Syngene International Limited’s consolidated net profit decreased by 88.56 percent YOY, reaching Rs. 15 crore compared to Rs. 131.1 crore during the same period last year. As compared to Q2 FY26, the net profit has decreased by 77.65 percent, from Rs. 67.10 crore. The basic earnings per share decreased by 88.69 percent and stood at Rs. 0.37 as against Rs. 3.27 recorded in the same quarter in the previous year, FY2025.

Syngene International Limited’s revenue and net profit have grown at a CAGR of 11.83 percent and 7.79 percent, respectively, over the last three years. In terms of return ratios, the company’s ROCE and ROE stand at 13.5 percent and 10.5 percent, respectively. Syngene International Limited has an earnings per share (EPS) of Rs. 8.74, and its debt-to-equity ratio is 0.12x.

Syngene International Limited serves a broad global client base of ~400 active clients, including 14 of the top 20 pharmaceutical companies. The company has built a strong innovation-led platform with over 400 patents held jointly with clients. 

As of March 31, 2025, Syngene had a total headcount of 8,235, comprising 5,641 scientists, with a highly skilled workforce including 51 percent Master’s degree holders, 7 percent PhDs, and 42 percent others, enabling delivery of high-quality, end-to-end scientific solutions and a sustained competitive advantage.

Syngene International Limited partners with leading global organizations across pharmaceuticals, biotechnology, animal health, consumer goods, and specialty chemicals, including Bristol Myers Squibb, Sanofi, Novartis, Amgen, Merck, Zoetis, Elanco, FMC, Dow AgroSciences, Givaudan, Beiersdorf, Essilor, Kraton, and Purina, highlighting its strong global partnerships and cross-industry capabilities.

Syngene International Limited was established in 1993 and is headquartered in Bengaluru, India. The company is a leading contract research, development, and manufacturing organization (CRDMO) and engages in integrated scientific services from early drug discovery to commercial supply.

The company supports global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors through discovery chemistry, biology, preclinical development, API manufacturing, and clinical trials. The company’s state-of-the-art facilities are located in Bangalore, Hyderabad, and Mangalore.

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post Syngene International Share Price Crashes 5% After Massive Q3 Net Profit Decline appeared first on Trade Brains.